Caribou Biosciences Inc
NASDAQ:CRBU 11:08:08 AM EDT
Earnings Announcements
Caribou Biosciences Reports Fourth Quarter Loss Per Share Of $0.31
Published: 03/21/2022 20:14 GMT
Caribou Biosciences Inc (CRBU) - Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update.
Caribou Biosciences Inc - Had $413.5 Million in Cash, Cash Equivalents, and Marketable Securities As of December 31, 2021.
Caribou Biosciences Inc Qtrly Loss per Share $0.31.
Caribou - Cash, Cash Equivalents, Marketable Securities As of Dec 31, 2021 Support Advancement of Allogeneic Car-t and Car-nk Cell Therapies.
Caribou Biosciences Inc - Had $413.5 Million in Cash, Cash Equivalents, and Marketable Securities As of December 31, 2021.
Caribou Biosciences Inc Qtrly Loss per Share $0.31.
Caribou - Cash, Cash Equivalents, Marketable Securities As of Dec 31, 2021 Support Advancement of Allogeneic Car-t and Car-nk Cell Therapies.
Revenue is expected to be $2.86 Million
Adjusted EPS is expected to be -$0.36
Next Quarter Revenue Guidance is expected to be $3.54 Million
Next Quarter EPS Guidance is expected to be -$0.38
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.36
Next Quarter Revenue Guidance is expected to be $3.54 Million
Next Quarter EPS Guidance is expected to be -$0.38
More details on our Analysts Page.